Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient

Journal of Clinical Virology

Volumn 49, Issue 2, 2010, Pages 131-133

  Payer, B A ^a   Reiberger, T ^a   Rutter, K ^a   Beinhardt, S ^a   Staettermayer, A F ^a   Peck Radosavljevic, M ^a   Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HCV; HIV; Nonresponse; Pegylated interferon; Ribavirin; Silibinin

Indexed keywords

INTERLEUKIN 28; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SILIBININ; SILYMARIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MIXED INFECTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRESCRIPTION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VERTIGO; VIROTHERAPY; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; SILYMARIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77956649719     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.07.006     Document Type: Article

References (11)

1. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
2. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:S6-S9.
3. Chen T.Y., Ding E.L., Seage Iii G.R., Kim A.Y. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49:1605-1615.
4. Torriani F.J., Rodriguez-Torrez M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
5. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
6. Soriano V., Maida I., Nunez M., Garcia-Samaniego J., Barreiro P., Martin-Carbonero L., et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004, 9:987-992.
7. Dieterich D.T., Rizzetto M., Manns M.P. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. J Viral Hepatitis 2009, 16:833-843.
8. Sulkowski M.S. Specific targeted antiviral therapy for hepatitis C. Curr Gastroenterol Rep 2007, 9:5-13.
9. Ferenci P., Scherzer T.M., Kerschner H., Rutter K., Beinhardt S., Hofer H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135:1561-1567.
10. Ahmed-Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2009.
11. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.